newsfilter
← Latest News
GlobeNewswire·

University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

TORONTO, March 15, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., ("Arch" or the "Company") (TSXV:ARCH, OTCQB:ACHFF), announced today that a research team from the University of Calgary's Cumming School of Medicine